Morepen Q1 Profit Drops Nearly 68%

  Published 10 months ago

Morepen Laboratories’ Q1 FY26 PBT slumped 67.79% YoY amid rising finance costs and employee-related expenses.

  • Finance cost soared 250.43% YoY, significantly impacting quarterly profit despite marginal rise in overall expenses.
  • Material and employee expenses rose 1.14% and 15.18% YoY respectively, adding to cost pressures in Q1 FY26.
  • Global pharma player with strong API and wellness portfolio, Morepen operates in 80+ countries across key healthcare segments.
You might like these

UBS Flags Ad Shift at Zee

India's Net Non-Resident Claims Drop to $330 Billion in Q4 2024-25

MCX Slips Amid Technical Glitch

Container Corp India Announces Bonus Shares Allotment

Senco Gold Surges 5% on Strong Q1 Sales

BSE Shares Drop as Derivatives Expiry Shift Sparks Concerns

Indian Refiner Stocks Up as Crude Falls

News that matters the most ⚡